Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational cell therapy consisting of allogeneic adipose-derived mesenchymal stem cells (MSCs) developed by Liaocheng People's Hospital for the treatment of moderate to severe ulcerative colitis. These MSCs are adult stem cells harvested from adipose tissue that possess the ability to home to sites of mucosal damage. Once at the site of inflammation, they exert immunomodulatory and anti-inflammatory effects by secreting paracrine factors, which help reduce colonic inflammation and promote functional recovery of the damaged intestinal mucosa. The therapy is currently being evaluated in a Phase I/II clinical trial (NCT03609905) where it is administered via intracolonic injection using a colonoscope.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic adipose-derived mesenchymal stem cells (Liaocheng People's Hospital).